--- title: "4,135 Shares in HCA Healthcare, Inc. (NYSE:HCA) Bought by Atria Investments Inc" description: "Atria Investments Inc has bought 4,135 shares of HCA Healthcare, Inc. The stake is valued at approximately $1,379,000. Other institutional investors have also recently bought and sold shares of the st" type: "news" locale: "en" url: "https://longbridge.com/en/news/210887938.md" published_at: "2024-08-06T15:35:19.000Z" --- # 4,135 Shares in HCA Healthcare, Inc. (NYSE:HCA) Bought by Atria Investments Inc > Atria Investments Inc has bought 4,135 shares of HCA Healthcare, Inc. The stake is valued at approximately $1,379,000. Other institutional investors have also recently bought and sold shares of the stock. Insiders have sold a significant number of company shares. HCA Healthcare's stock performance has been positive. The company recently announced a quarterly dividend. Atria Investments Inc bought a new stake in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,135 shares of the company's stock, valued at approximately $1,379,000. Get **HCA Healthcare** alerts: - Healthcare Stock Rides the Acute Services Phenomenon to New Highs Several other institutional investors also recently bought and sold shares of the stock. Swedbank AB acquired a new stake in shares of HCA Healthcare in the first quarter valued at about $95,882,000. Virtu Financial LLC acquired a new stake in HCA Healthcare during the first quarter worth about $537,000. Heartland Bank & Trust Co acquired a new stake in HCA Healthcare during the first quarter worth about $215,000. Plato Investment Management Ltd grew its position in HCA Healthcare by 665.9% during the first quarter. Plato Investment Management Ltd now owns 3,140 shares of the company's stock worth $1,047,000 after buying an additional 2,730 shares in the last quarter. Finally, Vista Investment Partners LLC grew its position in HCA Healthcare by 1.7% during the first quarter. Vista Investment Partners LLC now owns 7,963 shares of the company's stock worth $2,656,000 after buying an additional 130 shares in the last quarter. 62.73% of the stock is currently owned by institutional investors. ## Insiders Place Their Bets In other news, SVP Jeffrey E. Cohen sold 1,650 shares of the company's stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $313.00, for a total value of $516,450.00. Following the completion of the sale, the senior vice president now directly owns 5,185 shares in the company, valued at approximately $1,622,905. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Jeffrey E. Cohen sold 1,650 shares of the company's stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $313.00, for a total transaction of $516,450.00. Following the sale, the senior vice president now directly owns 5,185 shares of the company's stock, valued at approximately $1,622,905. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael S. Cuffe sold 6,311 shares of the business's stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $316.88, for a total value of $1,999,829.68. Following the transaction, the executive vice president now owns 29,624 shares of the company's stock, valued at approximately $9,387,253.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,668 shares of company stock valued at $6,309,885. Insiders own 1.60% of the company's stock. ## HCA Healthcare Stock Performance - Top 4 Must-Have Healthcare Stocks for Long-Term Growth Shares of NYSE HCA traded up $6.86 during midday trading on Tuesday, hitting $357.04. The company's stock had a trading volume of 149,072 shares, compared to its average volume of 1,159,466. HCA Healthcare, Inc. has a one year low of $215.96 and a one year high of $369.41. The firm has a market capitalization of $93.51 billion, a price-to-earnings ratio of 17.47, a P/E/G ratio of 1.39 and a beta of 1.68. The company has a current ratio of 1.06, a quick ratio of 0.94 and a debt-to-equity ratio of 27.11. The stock has a fifty day moving average price of $334.83 and a 200 day moving average price of $325.15. HCA Healthcare (NYSE:HCA - Get Free Report) last released its quarterly earnings results on Tuesday, July 23rd. The company reported $5.50 EPS for the quarter, beating analysts' consensus estimates of $4.97 by $0.53. The firm had revenue of $17.49 billion during the quarter, compared to analyst estimates of $17.05 billion. HCA Healthcare had a net margin of 8.40% and a return on equity of 553.13%. The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $4.29 EPS. On average, research analysts forecast that HCA Healthcare, Inc. will post 22.43 EPS for the current fiscal year. ## HCA Healthcare Announces Dividend - These are the Top 4 Stocks for Buybacks in 2024 The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 16th will be paid a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date is Monday, September 16th. HCA Healthcare's dividend payout ratio is 13.16%. ## Analyst Upgrades and Downgrades HCA has been the topic of a number of recent research reports. Robert W. Baird initiated coverage on HCA Healthcare in a report on Thursday, May 30th. They set an "outperform" rating and a $396.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on HCA Healthcare from $327.00 to $332.00 and gave the company a "neutral" rating in a report on Thursday, May 30th. SVB Leerink lifted their price objective on HCA Healthcare from $367.00 to $396.00 and gave the company an "outperform" rating in a report on Wednesday, July 24th. Barclays lifted their target price on shares of HCA Healthcare from $376.00 to $396.00 and gave the company an "overweight" rating in a research note on Wednesday, July 24th. Finally, Wells Fargo & Company boosted their price objective on shares of HCA Healthcare from $315.00 to $365.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $344.06. **Read Our Latest Research Report on HCA** ## HCA Healthcare Profile (Free Report) HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. ## Featured Stories - Five stocks we like better than HCA Healthcare - What is an Earnings Surprise? - Hims & Hers Reports Stellar Quarter: Stock Set for a Rally - How to Use the MarketBeat Excel Dividend Calculator - Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance - How to Invest in Biotech Stocks - Palantir Stock Surges After Strong Earnings: Is $30 Too Low? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* → We recommended Nvidia in 2016, now we’re recommending this… (From Porter & Company) (Ad)## Should you invest $1,000 in HCA Healthcare right now? Before you consider HCA Healthcare, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list. While HCA Healthcare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [HCA.US - HCA Healthcare](https://longbridge.com/en/quote/HCA.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | MBL Wealth LLC Takes $1.23 Million Position in HCA Healthcare, Inc. $HCA | MBL Wealth LLC acquired 2,891 shares of HCA Healthcare, valued at approximately $1.23 million, during the 3rd quarter, a | [Link](https://longbridge.com/en/news/270852490.md) | | Jim Cramer on HCA Healthcare: “I think it’s a terrific one to buy” | Jim Cramer is bullish on HCA Healthcare (NYSE:HCA) due to its share buyback activity, which has significantly reduced it | [Link](https://longbridge.com/en/news/270408434.md) | | Do Wall Street Analysts Like Quest Diagnostics Stock? | Do Wall Street Analysts Like Quest Diagnostics Stock? | [Link](https://longbridge.com/en/news/276222261.md) | | Do Wall Street Analysts Like CMS Energy Stock? | Do Wall Street Analysts Like CMS Energy Stock? | [Link](https://longbridge.com/en/news/276064675.md) | | Satellos Bioscience to Court Investors as Phase 2 DMD Program Advances | Satellos Bioscience (TSE:MSCL) is set to engage investors at several healthcare conferences in late February and early M | [Link](https://longbridge.com/en/news/276358401.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.